Natalizumab
- PDF / 169,361 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 77 Downloads / 143 Views
1 S
Natalizumab Immune-reconstitution inflammatory syndrome following natalizumab withdrawal: case report
A 35-year-old woman developed immune-reconstitution inflammatory syndrome (IRIS) following natalizumab withdrawal. The woman had been diagnosed with relapsing-remitting multiple sclerosis at the age of 19 years. Despite various unspecified disease-modifying therapies, her disease remained active. She subsequently started receiving natalizumab [dosage and route not stated]. However, 1 year later, she was brought to the emergency department with altered level of consciousness over 24h. She was hospitalised. Anamnesis revealed that 2 months prior to her admission, she had stopped natalizumab therapy by herself. MRI findings revealed about a hundred white matter ovoid-lesions with open-ring enhancement, suggestive of IRIS. The woman was treated with intensive steroids and made a complete recovery after 1 month. Thereafter, she was discharged; her symptoms were attributed to IRIS secondary to natalizumab withdrawal. Ciano Petersen NL, et al. Immune-reconstituion inflammatory syndrome in multiple sclerosis, are all severe cases associated with a bad prognosis. European Journal of 803498430 Neurology 27 (Suppl. 1): 976 (plus poster) abstr. EPO2340, May 2020. Available from: URL: https://onlinelibrary.wiley.com/doi/10.1111/ene.14308 [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
